ACS chemical neuroscience molecule spotlight on Qnexa.
Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity. Vivus, Inc. has demonstrated efficacy of their product and are currently addressing FDA safety concerns with the possibility of a New Drug Application (NDA) resubmission.
Department of Pharmaceutical Sciences,  Lipscomb University College of Pharmacy , One University Park Drive, Nashville, Tennessee 37204, United States.
Susan L
SL
Mercer
D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000494:pharmacology / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D015897:Comorbidity; D004311:Double-Blind Method; D017277:Drug Approval; D004338:Drug Combinations; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D050177:Overweight / Q000188:drug therapy; D010645:Phentermine / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077236:Topiramate; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D015431:Weight Loss / Q000187:drug effects
D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D004338:Drug Combinations; C577572:Qnexa; D000077236:Topiramate; D005632:Fructose; D010645:Phentermine